5 completed, 1 terminated. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
Follow ovcon 35: new trials by email Literature Review of ovcon 35 trials Research Report on ovcon 35
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug Interaction Study of Danicopan Danicopan, Warfarin, Bupropion - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 52 | 2019-07-28 | 2021-01-14 |
| A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol - Solid Cancers | Phase 1 | Completed | Genentech, Inc. | 52 | 2010-11-01 | 2015-06-29 |
| Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions Norethindrone/Ethinyl Estradiol, FEMCON® Fe - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 36 | 2008-08-01 | 2011-05-30 |
| A Pharmacokinetic Study of Colchicine With an Oral Contraceptive Norethindrone/Ethinyl Estradiol, Colchicine, Placebo (for Colchicine) - Pharmacokinetics | Phase 1 | Completed | Mutual Pharmaceutical Company, Inc. | 30 | 2007-08-01 | 2010-01-05 |
| Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions Norethindrone/Ethinyl Estradiol, Ovcon® 35 Fe - Bioequivalence | Phase 1 | Completed | Teva Pharmaceuticals USA | 36 | 2006-12-01 | 2011-05-25 |
| Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers Tipranavir low dose, Tipranavir high dose, Ritonavir low dose - Healthy | Phase 1 | Terminated | Boehringer Ingelheim | 52 | 2002-05-01 | 2014-09-19 |
Teva Pharmaceuticals USA (2) · Alexion Pharmaceuticals, Inc. (1) · Boehringer Ingelheim (1) · Genentech, Inc. (1) · Mutual Pharmaceutical Company, Inc. (1)
United States (5)